Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arcus Biosciences (RCUS – Research Report), ...
Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...
21h
Zacks Investment Research on MSNPharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results